Literature DB >> 35101151

Heterozygous POLG variant Ser1181Asn co-segregating in a family with autosomal dominant axonal neuropathy, proximal muscle fatigability, ptosis, and ragged red fibers.

Maike F Dohrn1,2, Corina Heller3,4, Diana Zengeler3,4, Carolin D Obermaier3,4, Saskia Biskup3,4, Joachim Weis5, Stefan Nikolin5, Kristl G Claeys6,7, Ulrike Schöne8, Danique Beijer9, Natalie Winter10, Pascal Achenbach8,5, Burkhard Gess8, Jörg B Schulz8,11, Lejla Mulahasanovic3,4.   

Abstract

By whole-exome sequencing, we found the heterozygous POLG variant c.3542G>A; p.Ser1181Asn in a family of four affected individuals, presenting with a mixed neuro-myopathic phenotype. The variant is located within the active site of polymerase gamma, in a cluster region associated with an autosomal dominant inheritance. In adolescence, the index developed distal atrophies and weakness, sensory loss, afferent ataxia, double vision, and bilateral ptosis. One older sister presented with Charcot-Marie-Tooth-like symptoms, while the youngest sister and father reported exercise-induced muscle pain and proximal weakness. In none of the individuals, we observed any involvement of the central nervous system. Muscle biopsies obtained from the father and the older sister showed ragged-red fibers, and electron microscopy confirmed mitochondrial damage. We conclude that this novel POLG variant explains this family's phenotype.
© 2022. The Author(s).

Entities:  

Keywords:  Autosomal dominant; Axonal neuropathy; Mitochondrial myopathy; Myo-neuropathy; Polymerase gamma

Year:  2022        PMID: 35101151      PMCID: PMC8805222          DOI: 10.1186/s42466-022-00169-w

Source DB:  PubMed          Journal:  Neurol Res Pract        ISSN: 2524-3489


Case report

In her teenage years, the currently 57-year-old female index patient noticed progressive gait instability, distal muscle weakness, and distal sensory deficits. Fine motor skills worsened, and her vision became remotely doubled with fatigability. Clinically, she showed an advanced distal tetraparesis including steppage gait, sensory deficits on lower legs, afferent ataxia, distal areflexia, and a slight bilateral non-dynamic ptosis. Nerve conduction studies (NCS) confirmed a severe chronic axonal sensorimotor polyneuropathy. A detailed patient history and repeated laboratory tests did not reveal any acquired cause of neuropathy. The index patient (II.3) had two older and one younger sister, of whom the second (II.2) and fourth (II.4) born had neuromuscular symptoms as well, while the oldest sister (II.1) was unaffected (Fig. 1a). Patient II.2 presented with moderate weakness and atrophies in lower legs, distal sensory deficits, hyporeflexia, and pedes cavi. Patient II.4 reported proximal muscle weakness, exercise-induced muscle pain, and cramping. She had previously undergone surgery for bilateral ptosis. Their father (I.1) suffered from proximal muscle weakness and atrophies. His serum creatine kinase was moderately elevated (around 600 U/l; normal < 190 U/l), which was not the case in any of his daughters. NCS revealed an axonal sensorimotor polyneuropathy in patient I.1 and II.2, but not in patient II.4. We did not observe any significant decrement in the 3 Hz repetitive muscle stimulation. An electromyogram performed in patient I.1 at the left tibial anterior muscle showed a mixed neuropathic and myopathic pattern.
Fig. 1

Pedigree, clinical picture, and electron microscopy. In a family with an affected father, three affected and one unaffected sisters, the novel POLG variant c.3542G>A; p.Ser1181Asn co-segregates with the phenotype in two generations (a). Clinical features are distal atrophies and high-arched feet in the first (II.2) and second (II.3) oldest affected sister sitting on the right side and in the middle of the bench (b). The youngest sister (II.4) has a pronounced myopathic phenotype. An electron microscopy of the lateral vastus muscle obtained from patient II.2 revealed prominent intermyofibrillar autophagic vacuoles filled with pleomorphic granular and membranous material (c), degenerating mitochondria undergoing (abnormal) mitophagy (arrows; d, e), and paracrystalline inclusions in many mitochondria (arrows, f), demonstrating mitochondrial damage

Pedigree, clinical picture, and electron microscopy. In a family with an affected father, three affected and one unaffected sisters, the novel POLG variant c.3542G>A; p.Ser1181Asn co-segregates with the phenotype in two generations (a). Clinical features are distal atrophies and high-arched feet in the first (II.2) and second (II.3) oldest affected sister sitting on the right side and in the middle of the bench (b). The youngest sister (II.4) has a pronounced myopathic phenotype. An electron microscopy of the lateral vastus muscle obtained from patient II.2 revealed prominent intermyofibrillar autophagic vacuoles filled with pleomorphic granular and membranous material (c), degenerating mitochondria undergoing (abnormal) mitophagy (arrows; d, e), and paracrystalline inclusions in many mitochondria (arrows, f), demonstrating mitochondrial damage Whole-exome sequencing performed in patients II.2 and II.3 revealed the heterozygous variant c.3542G>A; p.Ser1181Asn in POLG (NM_001126131.3). Sanger sequencing-based segregation analyses confirmed that all affected family members carried the variant, whereas the unaffected sister (II.1) did not (Fig. 1a, b). A muscle biopsy obtained from patient II.2’s right lateral vastus muscle showed signs of denervation as well as a combination of COX-negative and ragged red fibers, which had previously been reported in the father’s muscle as well (analysis performed elsewhere). Additionally, the electron microscopy revealed degenerating mitochondria with para-crystalline inclusions as well as mitochondria undergoing impaired mitophagy (Fig. 1c–f).

Discussion

Polymerase gamma (POLG) is a 140 kDa enzyme responsible for mitochondrial DNA replication [3]. The spectrum of POLG-associated phenotypes is broad, and there is currently no disease-modifying treatment available. With an autosomal recessive mode of inheritance, mtDNA depletion syndromes such as Alpers-Huttenlocher syndrome cause severe encephalopathies with epilepsy, ataxia, parkinsonism, and mental retardation with an onset at early childhood [10]. Autosomal dominant disease forms are caused by variants clustering within the DNA-binding palm- and finger-domains [1] and typically manifest with a variable form of external ophthalmoplegia [4], frequently accompanied by generalized myopathy, tremor, or parkinsonism [5]. Axonal neuropathies are part of the known POLG spectrum [7, 12], typically with a sensory-ataxic phenotype [6]. It is further known that the age of onset and the severity of symptoms can vary even within carriers of dominant POLG mutations [2], like in the herein reported family. Co-segregating in a pedigree of autosomal dominant inheritance, we herein report the heterozygous POLG variant c.3542G>A; p.Ser1181Asn, for the first time in association with any disease. The variant is located within a hot spot region encoding the polymerase active site: “Holding” the template DNA strand, the so-called palm domain together with the finger and thumb domains are crucial for mitochondrial DNA replication [3, 8, 11]. Functional studies on the variant p.Tyr955Cys, likewise associated with a dominant mode of inheritance [5], showed a significantly reduced nucleotide incorporation rate with a higher amount of replication errors [9]. In-silico predictions for the novel variant c.3542G>A; p.Ser1181Asn consistently support its pathogenicity. In the gnomAD population database, the overall allele frequency is 0.00003182, with a total of nine heterozygotes, which might be explained by a reduced penetrance, a phenomenon that has been previously described for other pathogenic POLG variants. We conclude that the herein described heterozygous variant c.3542G>A; p.Ser1181Asn in POLG is likely to explain the patients’ phenotype. In families with a variable neuro-myopathic syndrome and autosomal dominant inheritance, we would consider POLG as a fitting molecular genetic cause.
  12 in total

Review 1.  DNA polymerases: structural diversity and common mechanisms.

Authors:  T A Steitz
Journal:  J Biol Chem       Date:  1999-06-18       Impact factor: 5.157

2.  Mutations of mitochondrial DNA polymerase gammaA are a frequent cause of autosomal dominant or recessive progressive external ophthalmoplegia.

Authors:  Eleonora Lamantea; Valeria Tiranti; Andreina Bordoni; Antonio Toscano; Francesco Bono; Serena Servidei; Alex Papadimitriou; Hans Spelbrink; Laura Silvestri; Giorgio Casari; Giacomo P Comi; Massimo Zeviani
Journal:  Ann Neurol       Date:  2002-08       Impact factor: 10.422

Review 3.  DNA polymerase gamma in mitochondrial DNA replication and repair.

Authors:  Maria A Graziewicz; Matthew J Longley; William C Copeland
Journal:  Chem Rev       Date:  2006-02       Impact factor: 60.622

4.  A diagnostic flow chart for POLG-related diseases based on signs sensitivity and specificity.

Authors:  Maya Tchikviladzé; Mylène Gilleron; Thierry Maisonobe; Damien Galanaud; Pascal Laforêt; Alexandra Durr; Bruno Eymard; Fanny Mochel; Hélène Ogier; Anthony Béhin; Tanya Stojkovic; Bertrand Degos; Isabelle Gourfinkel-An; Frederic Sedel; Mathieu Anheim; Alexis Elbaz; Karine Viala; Marie Vidailhet; Alexis Brice; Claude Jardel; Anne Lombès
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-08-11       Impact factor: 10.154

5.  Active site mutation in DNA polymerase gamma associated with progressive external ophthalmoplegia causes error-prone DNA synthesis.

Authors:  Mikhail V Ponamarev; Matthew J Longley; Dinh Nguyen; Thomas A Kunkel; William C Copeland
Journal:  J Biol Chem       Date:  2002-03-15       Impact factor: 5.157

6.  Clinical and genetic heterogeneity in progressive external ophthalmoplegia due to mutations in polymerase gamma.

Authors:  Massimiliano Filosto; Michelangelo Mancuso; Yutaka Nishigaki; Jacklyn Pancrudo; Yadollah Harati; Clifton Gooch; Ami Mankodi; Lydia Bayne; Eduardo Bonilla; Sara Shanske; Michio Hirano; Salvatore DiMauro
Journal:  Arch Neurol       Date:  2003-09

7.  Two families with autosomal dominant progressive external ophthalmoplegia.

Authors:  S Kiechl; R Horváth; P Luoma; U Kiechl-Kohlendorfer; B Wallacher-Scholz; R Stucka; C Thaler; J Wanschitz; A Suomalainen; M Jaksch; J Willeit
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

Review 8.  DNA polymerase gamma and mitochondrial disease: understanding the consequence of POLG mutations.

Authors:  Sherine S L Chan; William C Copeland
Journal:  Biochim Biophys Acta       Date:  2008-10-29

9.  Pathogenicity in POLG syndromes: DNA polymerase gamma pathogenicity prediction server and database.

Authors:  Anssi Nurminen; Gregory A Farnum; Laurie S Kaguni
Journal:  BBA Clin       Date:  2017-04-18

10.  "Mitochondrial neuropathies": A survey from the large cohort of the Italian Network.

Authors:  Michelangelo Mancuso; Daniele Orsucci; Corrado Angelini; Enrico Bertini; Valerio Carelli; Giacomo Pietro Comi; Antonio Federico; Carlo Minetti; Maurizio Moggio; Tiziana Mongini; Paola Tonin; Antonio Toscano; Claudio Bruno; Elena Caldarazzo Ienco; Massimiliano Filosto; Costanza Lamperti; Daria Diodato; Isabella Moroni; Olimpia Musumeci; Elena Pegoraro; Marco Spinazzi; Naghia Ahmed; Monica Sciacco; Liliana Vercelli; Anna Ardissone; Massimo Zeviani; Gabriele Siciliano
Journal:  Neuromuscul Disord       Date:  2016-02-23       Impact factor: 4.296

View more
  3 in total

1.  Heterozygous POLG variant Ser1181Asn is associated with autosomal dominant neuro-myopathy in one family with no further specific manifestations of mitochondrial syndrome.

Authors:  Maike F Dohrn; Danique Beijer; Lejla Mulahasanovic
Journal:  Neurol Res Pract       Date:  2022-07-11

2.  Carriers of POLG1 variants require investigations for multisystem disease and for mtDNA variations.

Authors:  Josef Finsterer; Sinda Zarrouk
Journal:  Neurol Res Pract       Date:  2022-07-11

Review 3.  Mitochondrial protein dysfunction in pathogenesis of neurological diseases.

Authors:  Liang Wang; Ziyun Yang; Xiumei He; Shiming Pu; Cheng Yang; Qiong Wu; Zuping Zhou; Xiaobo Cen; Hongxia Zhao
Journal:  Front Mol Neurosci       Date:  2022-09-07       Impact factor: 6.261

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.